



TEXAS HIV MEDICATION ADVISORY COMMITTEE MEETING

Date of Meeting: June 21, 2002
Number on Committee: Eleven (11)
Number Present: Eight (8)

OFFICIAL MINUTES

Members of Texas HIV Medication Advisory Committee: Stanley Britten, R. Ph., Fernando Garcia, M.D., Susan Gibson, R.N., Lisa James, L.M.S.W., Philip Keiser, M.D., Gary Maitre, Nancy Miertschin, M.P.H., Mark Miller, Mary Paul, M.D., Skip Rosenthal, and Natalie N. Vanek, M.D.

Attendance: All members were present except Lisa James, Mark Miller, and Stanley Britten.

TDH Staff in Attendance: Sharilyn Stanley, M.D., M.P.H., Linda Moore, John Allen, Debra Seamans, Dwayne Haught, Kelly Wharton, and Cindy Nissen.

Visitors: Richard Ponder, Johnson & Johnson; Laura Mandola and Michael Nastu, OrthoBiotech; Beth Null and Lillie Gilligan, GlaxoSmithKline; Don Stevens, Novartis; Suzanne Erickson and Holly Jacques, Merck & Co., Inc.; JoAnne Horgan, Achieve; Ron Schultz, Darryl Drug and Cynthia Garner, Abbott; Carolyn Parker, Texas AIDS Network; Keith Cromley, Visible Genetics; Marie Hatcher, Virologic; Brent Biggs and Glen Maxey, GCA; J. Scott Williams and Ann McDavid, Agouron; Michael Wright, Roche; Beverly Jimmerson, Consultant; E. Carter Hernandez, Consumer; Larry Diaz; Paul Mayfield, Consumer.

The meeting was held on June 21, 2002 at the Texas Animal Health Commission, located at 2105 Kramer Lane in Austin, Texas. Philip Keiser, M.D., Chair, called the meeting to order at approximately 12:00 noon.

Approval of Minutes:

Dr. Keiser asked the Committee to review the minutes from the April 26, 2002 meeting and then requested a motion be made to approve them. Dr. Vanek made the motion to approve, and the Committee unanimously approved the minutes.

Staff Reports:

John Allen gave a detailed staff report on active clients served and monthly THMP expenditures during the previous quarter. Dwayne Haught gave a summary report on the ADAP Educational Conference he attended in Washington, D.C. in May 2002. He mentioned that several states were experiencing budget shortfalls and constraints and that two states, North Carolina and Georgia, had capped enrollment on their programs and developed waiting lists, which was recommended only as a last resort by ADAP staff from other states. He also cautioned against comparing ADAPs with each other without also having a thorough knowledge of the states' Medicaid and local health program infrastructures. Dwayne reviewed projected budget shortfalls for Fiscal Years (FYs) 2002 through 2005. He also reported that the THMP received \$179,000 less for its FY2002 Federal Supplemental Grant. Dwayne attributed this reduction to more states applying for and receiving supplemental funds this year as compared to previous years. Linda Moore reviewed possible strategies that are being considered for reducing projected THMP budgetary shortfalls and living within the allotted budget. The strategies include: eliminating priority 2 and 3 drugs from the THMP formulary, changing eligibility requirements, and capping

program enrollment and developing a waiting list.

Dr. Garcia stated that he was in favor of cutting the priority 2 and 3 medications. Skip Rosenthal mentioned that the Committee should review the priority classifications to verify the drugs are classified in the proper priorities. Gary Maitre asked if there was any statutory guidance to the Committee or the THMP on health care outcome requirements; Dr. Stanley replied that the requirement was simply to administer a medication program. Dr. Vanek asked that THMP staff supply a report on client utilization of fluconazole over the months since the Committee waived the laboratory documentation requirements, as well as utilization figures for the recently approved formulary medications tenofovir and valgancyclovir.

The discussion turned to the drug Procrit, which was recommended for addition at the April 26, 2002 Advisory Committee meeting, but had yet to be finalized for approval by the Commissioner of Health. Skip mentioned that he was still in favor of adding the drug to the formulary; Dr. Keiser expressed his concern that the Committee would appear inconsistent by asking the Commissioner to approve a drug that's not cost-neutral to the formulary in light of the budgetary shortfall the program is projecting. Dr. Paul asked if the Committee could defer the addition of Procrit until additional funding is secured; Dr. Garcia agreed that the Committee should defer, as antiretroviral medications are most important to the formulary at this point. Nancy Miertschin made a motion to place a moratorium on adding any new drugs to the THMP's formulary at this time in light of the projected budgetary shortfall. Dr. Paul seconded the motion, and the motion passed by a majority with seven members in favor of a moratorium and Skip Rosenthal abstaining from voting. The Committee specified that this moratorium would also include Procrit, which was recommended for approval prior to receiving the notice that the THMP's Federal Supplemental Grant was cut by \$179,000.

Public Comments:

Carolyn Parker of the Texas AIDS Network (TAN) expressed her concern over the issues the Committee is facing, and stated that TAN considered securing additional funding for the THMP to be a top priority.

Next Meeting Date:

Dr. Keiser suggested Friday, September 13, 2002 as the tentative date for the next Committee meeting, to be confirmed at a later date. Dr. Keiser formally adjourned the meeting at approximately 2:30 p.m.

Approved By:

Philip H. Keiser, M.D.-Chairman, Texas HIV Medication Advisory Committee

Date